Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management
Bertin L., Crepaldi M., Zanconato M., Lorenzon G., Maniero D., de Barba C.
Clinical Trial on Autoimmune Research, published in Ther Adv Gastroenterol (2024) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Ther Adv Gastroenterol (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39711916
- PMCID
- PMC11660281
- DOI
- 10.1177/17562848241303651
- Citations
- 13
Abstract (original English)
Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria. Emerging therapies that target novel pathways offer promise in overcoming these limitations. This review explores the latest investigational drugs in phases I, II, and III clinical trials for treating both luminal and perianal CD. We highlight promising therapies that target known mechanisms, including selective Janus kinase inhibitors, anti-adhesion molecules, tumor necrosis factor inhibitors, and IL-23 selective inhibitors. In addition, we delve into novel therapeutic strategies such as sphingosine-1-phosphate receptor modulators, miR-124 upregulators, anti-fractalkine (CX3CL1), anti-TL1A, peroxisome proliferator-activated receptor gamma agonists, TGFBRI/ALK5 inhibitors, anti-CCR9 agents, and other innovative small molecules, as well as combination therapies. These emerging approaches, by addressing new pathways and mechanisms of action, have the potential to surpass the limitations of existing treatments and significantly improve CD
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ARandomized Controlled TrialPubMed
Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.
Randomized Controlled Trial with a reported sample of 283 on Autoimmune Research, published in Gastroenterology (2026) — summary generated from the PubMed abstract.
- 2026
- n = 283
Gastroenterology3 citations - Level ASystematic ReviewEurope PMC
Intraoperative Autologous Adipose-Derived Therapies and PRP as Add-On in the Surgical Treatment of Cryptoglandular and Crohn's Disease-Related Perianal Fistula-A Systematic Review
Systematic Review with a reported sample of 1017 on Autoimmune Research, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 1017
Bioengineering (Basel) - Level ASystematic ReviewEurope PMC
Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies
Systematic Review on Skin Aging, Chronic Inflammation, Autoimmune Research, published in Front Physiol (2026) — summary generated from the PubMed abstract.
- 2026
Front Physiol - Level ASystematic ReviewEurope PMC
Surgical interventions in inflammatory bowel disease: Indications, techniques, outcomes, and future directions
Systematic Review on Autoimmune Research, published in World J Gastrointest Pharmacol Ther (2026) — summary generated from the PubMed abstract.
- 2026
World J Gastrointest Pharmacol Ther - Level ASystematic ReviewEurope PMC
Management of Oro-Antral Communication: A Systemic Review of Diagnostic and Therapeutic Strategies
Systematic Review on Autoimmune Research, published in Diagnostics (Basel) (2025) — summary generated from the PubMed abstract.
- 2025
Diagnostics (Basel)5 citations